Schizophrenia, psychosis, and antipsychotic treatment — clinical research, new medications, and management strategies.
The FDA’s Psychopharmacologic Drugs Advisory Committee is evaluating a New Drug Application (NDA) for a combination of brexpiprazole and sertraline as a potential treatment for posttraumatic stress disorder…
Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term…
A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or…
Writing in Psychopharmacology Bulletin, Trishna Sharma, Annette C. Kestner and Abhishek Reddy described a 17-year-old female with a history of NT1 and no past psychiatric history presented to…
Writing in Psychopharmacology Bulletin, authors Chinenye Okoro, Kaye Homer, Marlene Kelbrick, Jonny Walker, Mary Sam, Justine Burge, Rosie Richards, Gabriela Paduret, and Feras Ali Mustafa examined a 53-year-old…
No pharmacological agents are approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis (DRP). Pimavanserin, an atypical antipsychotic that acts as a selective serotonin…
Johnson & Johnson thinks a longer-acting treatment against schizophrenia will help keep patients on their prescriptions and reduce their chances of a relapse. Now, with a FDA nod…
An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials…
By Sereen Rose Thomson, Navin Patil, Balaji Ommurugan, and Rajesh Krishna Bhandary Abstract Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses.…
By Johan Y. Cohen and Amélie Guilbault Abstract Due to the stringent regulatory environment for therapeutics, common side-effects of drugs in the general population are largely well-documented. This…
Allergan plc has announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of…
Original Investigation By Jari Tiihonen, MD, Ellenor Mittendorfer-Rutz, Maila Majak; et al Key Points Question Are there any clinically meaningful differences between specific antipsychotic medications or routes of administration regarding the risk…
In findings reported in a letter to the editor published online March 10 in Schizophrenia Research and reported by Medscape Medical News, the smoking cessation drug varenicline (Chantix)…
Abstract Many studies indicate a crucial role for the vitamin B12 and folate-dependent enzyme methionine synthase (MS) in brain development and function, but vitamin B12 status in the…
Rexulti: New treatment for schizophrenia and major depressive disorder approved and released by FDA On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to…
The US Food and Drug Administration (FDA) has approved an injectable, long-acting version of Alkermes Inc’s atypical antipsychotic aripiprazole to treat adults with schizophrenia. Aripiprazole lauroxil (Aristada) is…
